108 related articles for article (PubMed ID: 10383533)
1. Octreotide in refractory functional epigastric pain with nutritional impairment--an open study.
Ducrotte P; Maillot C; Leroi AM; Lalaude O; Colin R; Denis P
Aliment Pharmacol Ther; 1999 Jul; 13(7):969-75. PubMed ID: 10383533
[TBL] [Abstract][Full Text] [Related]
2. Octreotide for the treatment of diarrhoea in patients with ileal pouch anal anastomosis: a placebo-controlled crossover study.
Van Assche G; Ferrante M; Vermeire S; Noman M; Rans K; Van der Biest L; Penninckx F; Wolthuis A; Rutgeerts P; D'Hoore A
Colorectal Dis; 2012 Apr; 14(4):e181-6. PubMed ID: 21951549
[TBL] [Abstract][Full Text] [Related]
3. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
Nikou GC; Toumpanakis C; Katsiari C; Charalambopoulos D; Sfikakis PP
J Clin Rheumatol; 2007 Jun; 13(3):119-23. PubMed ID: 17551375
[TBL] [Abstract][Full Text] [Related]
4. Octreotide: a therapeutic option for idiopathic intracranial hypertension.
Panagopoulos GN; Deftereos SN; Tagaris GA; Gryllia M; Kounadi T; Karamani O; Panagiotidis D; Koutiola-Pappa E; Karageorgiou CE; Piadites G
Neurol Neurophysiol Neurosci; 2007 Jul; ():1. PubMed ID: 17700925
[TBL] [Abstract][Full Text] [Related]
5. Successful use of long-acting octreotide for intractable chronic gastrointestinal bleeding in children.
O'Meara M; Cicalese MP; Bordugo A; Ambrosi A; Hadzic N; Mieli-Vergani G
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):48-53. PubMed ID: 25162361
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome.
Penning C; Vecht J; Masclee AA
Aliment Pharmacol Ther; 2005 Nov; 22(10):963-9. PubMed ID: 16268971
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of octreotide-therapy in severe dumping syndrome.
Vecht J; Lamers CB; Masclee AA
Clin Endocrinol (Oxf); 1999 Nov; 51(5):619-24. PubMed ID: 10594523
[TBL] [Abstract][Full Text] [Related]
8. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure.
Vallurupalli S
Ann Pharmacother; 2010 Feb; 44(2):387-90. PubMed ID: 20118140
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of five days of subcutaneous octreotide treatment after sclerotherapy in preventing rebleeding from esophageal varices.
Yücesoy M; Başkol M; Keklik M; Güven M; Sungur M; Gürsoy S; Güven K; Ozbakir O
Turk J Gastroenterol; 2004 Sep; 15(3):137-43. PubMed ID: 15492910
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
[TBL] [Abstract][Full Text] [Related]
11. Octreotide therapy in dumping syndrome: Analysis of long-term results.
Didden P; Penning C; Masclee AA
Aliment Pharmacol Ther; 2006 Nov; 24(9):1367-75. PubMed ID: 17059518
[TBL] [Abstract][Full Text] [Related]
12. Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels.
Befon S; Mystakidou K; Lyra M; Tubanakis N; Vlahos L
Anticancer Res; 2000; 20(5C):4039-46. PubMed ID: 11268498
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of continuous subcutaneous octreotide used in combination with other drugs.
Mercadante S
J Palliat Care; 1995; 11(4):14-6. PubMed ID: 8648516
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of Octreotide LAR vs. octreotide tid for pain and quality of life in chronic pancreatitis.
Lieb JG; Shuster JJ; Theriaque D; Curington C; Cintrón M; Toskes PP
JOP; 2009 Sep; 10(5):518-22. PubMed ID: 19734628
[TBL] [Abstract][Full Text] [Related]
15. Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series.
Shah D; Sinn JK
Acta Paediatr; 2012 Apr; 101(4):e151-5. PubMed ID: 22092874
[TBL] [Abstract][Full Text] [Related]
16. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
Topkan E; Karaoglu A
Oncology; 2006; 71(5-6):354-60. PubMed ID: 17873499
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy of octreotide LAR in the treatment of Crohn's disease associated refractory diarrhea.
Martelli L; Colard A; Fontaine F; Deflandre J; Bastens B; Louis E
Scand J Gastroenterol; 2017 May; 52(5):564-569. PubMed ID: 28270045
[TBL] [Abstract][Full Text] [Related]
18. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
Rosenoff S
Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
[TBL] [Abstract][Full Text] [Related]
19. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
Shima Y; Ohtsu A; Shirao K; Sasaki Y
Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
